FDA approves first biosimilar to Neulasta

5 June 2018
biosimilars_samples_large

The US Food and Drug Administration has approved Fulphila (pegfilgrastim-jmbd), a biosimilar to Amgen’s (Nasdaq: AMGN) Neulasta(pegfilgrastim).

Fulphila has been approved to reduce the duration of febrile neutropenia (fever or other signs of infection with a low count of neutrophils, a type of white blood cells) in patients treated with chemotherapy in certain types of cancer.

The biosimilar was co-developed by Netherlands-incorporated Mylan (Nasdaq: MYL) and India’s Biocon BSE: 532523), with news of the long awaited approval sending Mylan’s share up 5.2% to $40.50 in after-hours trading on Monday, while Amgen fell 1.7% to $182.30.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars